Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Journal of Neuroscience
  • Log in
  • My Cart
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE
PreviousNext
Articles, Neurobiology of Disease

The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects

Christoph Wiessner, Karl-Heinz Wiederhold, Alain C. Tissot, Peter Frey, Simone Danner, Laura H. Jacobson, Gary T. Jennings, Rainer Lüönd, Rainer Ortmann, Julia Reichwald, Mauro Zurini, Anis Mir, Martin F. Bachmann and Matthias Staufenbiel
Journal of Neuroscience 22 June 2011, 31 (25) 9323-9331; DOI: https://doi.org/10.1523/JNEUROSCI.0293-11.2011
Christoph Wiessner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karl-Heinz Wiederhold
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain C. Tissot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Frey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simone Danner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura H. Jacobson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary T. Jennings
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rainer Lüönd
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rainer Ortmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Reichwald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mauro Zurini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anis Mir
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin F. Bachmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Staufenbiel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Immunization against amyloid-β (Aβ) can reduce amyloid accumulation in vivo and is considered a potential therapeutic approach for Alzheimer's disease. However, it has been associated with meningoencephalitis thought to be mediated by inflammatory T-cells. With the aim of producing an immunogenic vaccine without this side effect, we designed CAD106 comprising Aβ1–6 coupled to the virus-like particle Qβ. Immunization with this vaccine did not activate Aβ-specific T-cells. In APP transgenic mice, CAD106 induced efficacious Aβ antibody titers of different IgG subclasses mainly recognizing the Aβ3–6 epitope. CAD106 reduced brain amyloid accumulation in two APP transgenic mouse lines. Plaque number was a more sensitive readout than plaque area, followed by Aβ42 and Aβ40 levels. Studies with very strong overall amyloid reduction showed an increase in vascular Aβ, which atypically was nonfibrillar. The efficacy of Aβ immunotherapy depended on the Aβ levels and thus differed between animal models, brain regions, and stage of amyloid deposition. Therefore, animal studies may not quantitatively predict the effect in human Alzheimer's disease. Our studies provided no evidence for increased microhemorrhages or inflammatory reactions in amyloid-containing brain. In rhesus monkeys, CAD106 induced a similar antibody response as in mice. The antibodies stained amyloid deposits on tissue sections of mouse and human brain but did not label cellular structures containing APP. They reacted with Aβ monomers and oligomers and blocked Aβ toxicity in cell culture. We conclude that CAD106 immunization is suited to interfere with Aβ aggregation and its downstream detrimental effects.

View Full Text
Back to top

In this issue

The Journal of Neuroscience: 31 (25)
Journal of Neuroscience
Vol. 31, Issue 25
22 Jun 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Advertising (PDF)
  • Ed Board (PDF)
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects
Christoph Wiessner, Karl-Heinz Wiederhold, Alain C. Tissot, Peter Frey, Simone Danner, Laura H. Jacobson, Gary T. Jennings, Rainer Lüönd, Rainer Ortmann, Julia Reichwald, Mauro Zurini, Anis Mir, Martin F. Bachmann, Matthias Staufenbiel
Journal of Neuroscience 22 June 2011, 31 (25) 9323-9331; DOI: 10.1523/JNEUROSCI.0293-11.2011

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
The Second-Generation Active Aβ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects
Christoph Wiessner, Karl-Heinz Wiederhold, Alain C. Tissot, Peter Frey, Simone Danner, Laura H. Jacobson, Gary T. Jennings, Rainer Lüönd, Rainer Ortmann, Julia Reichwald, Mauro Zurini, Anis Mir, Martin F. Bachmann, Matthias Staufenbiel
Journal of Neuroscience 22 June 2011, 31 (25) 9323-9331; DOI: 10.1523/JNEUROSCI.0293-11.2011
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Articles

  • Choice Behavior Guided by Learned, But Not Innate, Taste Aversion Recruits the Orbitofrontal Cortex
  • Maturation of Spontaneous Firing Properties after Hearing Onset in Rat Auditory Nerve Fibers: Spontaneous Rates, Refractoriness, and Interfiber Correlations
  • Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration
Show more Articles

Neurobiology of Disease

  • Lumateperone Normalizes Pathological Levels of Acute Inflammation through Important Pathways Known to Be Involved in Mood Regulation
  • Prolactin-Releasing Peptide Contributes to Stress-Related Mood Disorders and Inhibits Sleep/Mood Regulatory Melanin-Concentrating Hormone Neurons in Rats
  • mTORC2 Inhibition Improves Morphological Effects of PTEN Loss, But Does Not Correct Synaptic Dysfunction or Prevent Seizures
Show more Neurobiology of Disease
  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
(JNeurosci logo)
(SfN logo)

Copyright © 2023 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.